"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
NeoProfen may alter signs of infection. Patients' caregivers should be informed that the infant will be carefully monitored for any signs of infection.
Patients' caregivers should be informed that like other NSAIDS, NeoProfen can inhibit clot formation therefore their infant will be monitored for any signs of bleeding.
Patients' caregivers should be informed that the infants' blood will be tested for increased levels of total bilirubin.
Patients' caregivers should be informed that the infants' skin and tissues will be monitored as leakage from administration may be irritating to tissue.
Last reviewed on RxList: 12/12/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional NeoProfen Information
- NeoProfen Drug Interactions Center: ibuprofen lysine (pf) iv
- NeoProfen Side Effects Center
- NeoProfen FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.